Sun Pharmaceutical Industries (SUNPHARMA) Q1 24/25 earnings summary

Executive summary

• Q1 FY 2025 consolidated sales reached INR 125,245 million, up 6.3% year-over-year, with net profit at INR 28,356 million, a 40.2% increase over Q1 last year and 20.9% growth over adjusted net profit of Q1 FY 2024.

• EBITDA for Q1 was INR 36,076 million, up 8.3% year-over-year, with an EBITDA margin of 28.5% compared to 27.9% in Q1 FY 2024.

• EPS for the quarter was INR 11.8 per share.

• Taro is now fully consolidated as a private, wholly owned subsidiary after acquisition of all outstanding shares.

• US FDA approved Leqselvi (deuruxolitinib) for severe alopecia areata.

Financial highlights

• Consolidated revenue from operations for Q1 FY 2025 was INR 125,245 million, with total income at INR 131,853 million.

• R&D investments increased to INR 7,940 million from INR 6,796 million in Q1 FY 2024.

• India Formulation sales contributed 33.1% of total sales, US Formulations 31.1%, Emerging Markets 18.9%, and Rest of World 12.6%.

• Material cost was 21.4% of sales, lower year-over-year due to better product mix.

• Net cash position as of June 30, 2024, was $2.3 billion.

Outlook and guidance

• Effective tax rate expected to rise for the full year due to reduced exemptions.

• R&D spend is expected to step up in subsequent quarters, aiming for 8%-10% of sales for the year.

• Specialty R&D pipeline includes 6 new active substances in clinical studies, with several regulatory and clinical milestones anticipated.